Kolexia
Mayenga Marie Pneumologie
Mayenga Marie
Pneumologie
Hôpital Foch
Suresnes, France
40 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinome pulmonaire non à petites cellules Tumeurs du poumon Carcinome pulmonaire à petites cellules Hémorragie Thrombose Dyspnée Vaccine Hypertension artérielle Thrombose veineuse

Collaborateurs

Voir plus
Noel Johanna
Noel Johanna
Hôpital Européen Georges Pompidou, Paris, France
This Marie-Sophie
This Marie-Sophie
Centre hospitalier de Versailles, Le Chesnay, France
Julie Catherine
Julie Catherine
Hôpital Ambroise Paré, Boulogne-Billancourt, France
Giroux-Leprieur Etienne
Giroux-Leprieur Etienne
Hôpital Ambroise Paré, Boulogne-Billancourt, France

Industries

Voir plus
LVL Medical
2 collaboration(s)
Dernière en 2022
MSD
1 collaboration(s)
Dernière en 2022
AstraZeneca
1 collaboration(s)
Dernière en 2022
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands)   24 décembre 2023
1499P Wnt5-ROR2 signalling mediated resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
1496P Higher levels of CSF-1 support resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Cancer-Associated Thrombosis on Bevacizumab: Risk of Recurrence and Bleeding When Bevacizumab Is Stopped or Continued.
Cancers   31 juillet 2023
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Cancer immunology, immunotherapy : CII   22 mai 2023
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Cancer immunology, immunotherapy : CII   24 janvier 2023
Cancer associated thrombosis on bevacizumab: Risk of recurrence and bleeding if bevacizumab is stopped or continued
Abstracts of the ISTH 2022 Congress of the International Society of Thrombosis and Haemostasis, July 9–13, 2022   21 octobre 2022
1113P Real-world multicentre cohort of 1L pembrolizumab alone or in combination with platinum-based chemotherapy in NSCLC PD-L1 ≥ 50%
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab.
Cancer immunology, immunotherapy : CII   18 avril 2022
Marqueurs de recrutement et d’activation macrophagiques et réponse au traitement des cancers bronchiques non à petites cellules
Revue des maladies respiratoires   01 février 2022